Advertisement
Screener

Citius Pharmaceuticals, Inc. (CTXR) Proceeds from Notes Payable

2.8 / 5 stars · 68/120 Roast Me

Citius Pharmaceuticals, Inc. Proceeds from Notes Payable

Citius Pharmaceuticals, Inc. (CTXR) reported Proceeds from Notes Payable of $1.30 million for the 12-month period ending 2025-09-30, per its 10-K filed 2025-12-23.

Financial Statements › Cash Flow › Financing Activities

us-gaap:ProceedsFromNotesPayable · last filed 2025-12-23

  • Citius Pharmaceuticals, Inc. proceeds from notes payable for the quarter ending 2025-09-30 was $0.00.
  • Citius Pharmaceuticals, Inc. proceeds from notes payable for the quarter ending 2021-09-30 was $0.00.
  • Citius Pharmaceuticals, Inc. proceeds from notes payable for the quarter ending 2021-06-30 was $0.00.
  • Citius Pharmaceuticals, Inc. proceeds from notes payable for the quarter ending 2021-03-31 was $0.00.
  • Citius Pharmaceuticals, Inc. proceeds from notes payable for fiscal 2025 was $1.30M.
  • Citius Pharmaceuticals, Inc. proceeds from notes payable for fiscal 2021 was $500.00, a 99.70% decline from fiscal 2020.
  • Citius Pharmaceuticals, Inc. proceeds from notes payable for fiscal 2020 was $164.58K.
  • Citius Pharmaceuticals, Inc. proceeds from notes payable for fiscal 2016 was $500.00K.
Period endProceeds from Notes PayableProceeds from Notes Payable 3 monthProceeds from Notes Payable 6 monthProceeds from Notes Payable 9 monthProceeds from Notes Payable 12 month
2025-09-30$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23
$1.30M
10-K · filed 2025-12-23
2025-06-30$1.30M
10-Q · filed 2025-08-12
2025-05-28$300.00K
10-K · filed 2025-12-23
2023-05-08$15.00M
10-K · filed 2023-12-29
2021-09-30$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-15
$0.00
derived: sum of 2 quarters · filed 2021-12-15
$0.00
derived: sum of 3 quarters · filed 2021-12-15
$500.00
10-K · filed 2021-12-15
2021-06-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-12
$0.00
derived: sum of 2 quarters · filed 2021-08-12
$500.00
10-Q · filed 2021-08-12
$500.00
derived: sum of 4 quarters · filed 2021-08-12
2021-03-31$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-05-13
$500.00
10-Q · filed 2021-05-13
$500.00
derived: sum of 3 quarters · filed 2021-05-13
2020-12-31$500.00
10-Q · filed 2021-02-11
$500.00
derived: sum of 2 quarters · filed 2021-02-11
2020-09-30$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2020-12-16
$164.58K
10-K · filed 2020-12-16
2020-06-30$164.58K
10-Q · filed 2020-08-14
2016-12-31$820.00K
10-Q · filed 2017-02-14
2016-09-30$500.00K
10-K · filed 2016-12-23
2012-09-30$17.05K
10-Q · filed 2013-05-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
Korsana Biosciences, Inc. (CYCN)United States$0.016B
Lantern Pharma Inc. (LTRN)United States$0.015B-2.87
Anebulo Pharmaceuticals, Inc. (ANEB)United States$0.015B
ACTUATE THERAPEUTICS, INC. (ACTU)United States$0.015B
Pasithea Therapeutics Corp. (KTTA)United States$0.017B-0.81
Tvardi Therapeutics, Inc. (TVRD)United States$0.014B
Vyome Holdings, Inc (HIND)United States$0.014B-1.38
Allarity Therapeutics, Inc. (ALLR)United States$0.017B-1.66
BullFrog AI Holdings, Inc. (BFRG)United States$0.014B
PALATIN TECHNOLOGIES INC (PTN)United States$0.017B-5.36